Joint R&D 2024: Freezing of Reliable Oocytes after Screening with AI for women awaiting Cancer Treatment

Project Details

Description

Cancer treatment can significantly impact female fertility, prompting an urgent referral to the fertility clinic to discuss fertility preservation options. Oocyte cryopreservation has been endorsed as an approach to boost cancer patients’ hope of future motherhood through the use of assisted reproductive techniques (ARTs). Because objective measures linking oocyte quality with prospective pregnancy outcome are currently missing, the true potential of the cryopreserved oocytes, while being highly relevant for women with cancer before they initiate potentially gonadotoxic cancer treatment, is largely unpredictable. Brussels IVF collaborates with DIMA to explore AI's role in early decision-making in ART for women with cancer. This project combines medical imaging, computer vision, mathematical modeling, and deep learning to predict oocyte quality for pregnancy success. By leveraging AI advancements, this project embodies a transformative step forward in filling a critical gap between cancer care and reproductive health, and aims at providing improved services for women who are willing to navigate the complex intersection of cancer treatment and fertility preservation.
Short title or EU acronymFROSCT
AcronymBRGRD82
StatusActive
Effective start/end date1/05/24 → 30/04/27

Keywords

  • cancer
  • women
  • assisted reprodictive technology
  • artificial intelligence
  • oocyte
  • cryopreservation

Flemish discipline codes in use since 2023

  • Cancer therapy

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.